Company news
Recce Pharmaceuticals Ltd. news in 2022
Recce Pharmaceuticals Ltd.'s news releases, calls and decks from 2022, newest first.
Anti-Infective Research Unit est. at Murdoch Childrens
December 15, 2022
Approval to Start Phase I/II Diabetic Foot Ulcer Study
December 8, 2022
Anti-Infective Portfolio Update and Webinar details
October 18, 2022
Pause in trading
October 17, 2022
R327 COVID Study Update
October 17, 2022
Expansion and Acceleration of Clinical Programs
September 27, 2022
Appendix 4E
August 31, 2022
Phase I Clinical Trial of R327 I.V. - 6000mg Complete
August 21, 2022
Corporate Presentation - Aussie Equities Day 2022
July 28, 2022
Phase I Positive Safety Data - 4000mg Complete
June 21, 2022
Phase I Clinical Trial R327 Advances to 4000mg
May 20, 2022
Corporate Presentation - Biotech Investor Lunch
May 16, 2022
Phase I Clinical Trial R327 Advances to High Dose Cohort
April 12, 2022
Anti-Viral Patent Granted in Hong Kong
April 11, 2022
Positive safety data from 4th Cohort -Phase I Clinical Trial
March 29, 2022
$3.08m R&D Rebate Received
March 28, 2022
Safety Committee Clears PhI R327 Dose Increase
March 6, 2022
S&P DJI Announces March 2022 Quarterly Rebalance
March 4, 2022
Positive Safety Continues in 3rd Cohort PhI Clinical Trial
February 20, 2022
Positive Safety Data from Third Cohort of PI Clinical Trial
February 7, 2022
Positive Safety Data from Second Cohort of PI Clinical Trial
January 18, 2022
Positive Safety Data from Phase 1 Clinical Trial
January 6, 2022
Decks in 2022
- Investor Presentation (July 2022)
Investor deck · 21 slides · Jul 28, 2022
- Investor Presentation (May 2022)
Investor deck · 20 slides · May 16, 2022